PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. Jun 2012; 56(6): 2873–2878.
PMCID: PMC3370736
Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens
Carolina Garrido,corresponding authora Jorge Villacian,b Natalia Zahonero,a Theresa Pattery,b Federico Garcia,c Felix Gutierrez,d Estrella Caballero,e Margriet Van Houtte,b Vincent Soriano,corresponding authora and Carmen de Mendozaa, on behalf of the SINRES Group
aHospital Carlos III, Madrid, Spain
bVirco BVBA, Mechelen, Belgium
cHospital Clínico Universitario San Cecilio, Granada, Spain
dHospital General Universitario, Elche, Spain
eHospital Vall d'Hebrón, Barcelona, Spain
corresponding authorCorresponding author.
Address correspondence to Vincent Soriano, vsoriano/at/dragonet.es, or Carolina Garrido, garridocarolina/at/yahoo.es.
Received December 21, 2011; Revisions requested January 16, 2012; Accepted March 15, 2012.
The failure of raltegravir (RAL) is generally associated with the selection of mutations at integrase position Y143, Q148, or N155. However, a relatively high proportion of failures occurs in the absence of these changes. Here, we report the phenotypic susceptibilities to RAL and elvitegravir (EVG) for a large group of HIV-infected patients failing on RAL-containing regimens. Plasma from HIV-infected individuals failing on RAL-containing regimens underwent genotypic and phenotypic resistance testing (Antivirogram v2.5.01; Virco). A control group of patients failing on other regimens was similarly tested. Sixty-one samples were analyzed, 40 of which belonged to patients failing on RAL-containing regimens. Full RAL susceptibility was found in 20/21 controls, while susceptibility to EVG was diminished in 8 subjects, with a median fold change (FC) of 2.5 (interquartile range [IQR], 2.1 to 3.1). Fourteen samples from patients with RAL failures showed diminished RAL susceptibility, with a median FC of 38.5 (IQR, 10.8 to 103.2). Primary integrase resistance mutations were found in 11 of these samples, displaying a median FC of 68.5 (IQR, 23.5 to 134.3). The remaining 3 samples showed a median FC of 2.5 (IQR, 2 to 2.7). EVG susceptibility was diminished in 19/40 samples from patients with RAL failures (median FC, 7.71 [IQR, 2.48 to 99.93]). Cross-resistance between RAL and EVG was high (R2 = 0.8; P < 0.001), with drug susceptibility being more frequently reduced for EVG than for RAL (44.3% versus 24.6%; P = 0.035). Susceptibility to RAL and EVG is rarely affected in the absence of primary integrase resistance mutations. There is broad cross-resistance between RAL and EVG, which should preclude their sequential use. Resistance to EVG seems to be more frequent and might be more influenced by integrase variability.
The introduction of highly active antiretroviral therapy (HAART) has transformed the prognosis of HIV-positive patients, with dramatic improvements in survival. However, selection for drug resistance still represents a major challenge and promotes switches in therapeutic regimens for a substantial proportion of patients (3). Virologic failure with some antiretroviral drugs is associated with cross-resistance to agents within the same family, limiting rescue therapeutic options (16). Nevirapine and efavirenz are good examples of cross-resistance between members of the same drug family, almost completely sharing resistance patterns. To a lesser extent, this also occurs with failures of some protease inhibitors (12) and nucleoside analogues.
Integrase inhibitors (INIs) are a new and promising drug family for the treatment of HIV infection. Raltegravir (RAL) is the first-in-class approved drug for clinical use in both treatment-naïve (11) and treatment-experienced (19) individuals. Elvitegravir (EVG) will most likely be the second INI compound to be marketed (4). Resistance to INIs has been shown to be driven by changes located mainly in the central domain of the viral integrase. The results of clinical trials and clinical experience have highlighted that failure on RAL-containing regimens is generally driven by the selection of the mutations Y143RHC, Q148HRK, and/or N155H, often accompanied by secondary changes (G140SA, E138K, and L74M, etc.) (2). However, a relatively high proportion of patients does not show such changes upon virologic failure on RAL-containing regimens. Although unidentified resistance mutations might exist, a recent report highlighted that the absence of INI resistance mutations in these individuals is explained mainly by poor drug compliance, given that RAL plasma levels were undetectable in most of them (6).
Information about resistance to EVG in vivo is scarce. In the phase II GS-US-183-105 study (13), 28 individuals failed EVG after 24 weeks of treatment. Overall, 39% of them selected the E92Q mutation, 32% selected the Q148HRK mutation, and 25% selected the N155H mutation. Accordingly, broad cross-resistance between RAL and EVG should be expected. The aim of our study was to characterize RAL phenotypic susceptibilities in samples from a group of patients experiencing RAL failure, exploring whether mutations not previously involved in RAL resistance might be recognized and the extent of phenotypic cross-resistance to EVG.
Study population.
HIV-1-infected individuals treated at several clinics in Spain who experienced virological failure on a RAL-containing antiretroviral regimen were identified during 2009. Virological failure was defined as the first sample with plasma HIV RNA levels of >50 copies/ml, confirmed with a second specimen collected within a month. Plasma specimens collected at the time of the first RAL failure were then sent to Hospital Carlos III along with information on viral load, CD4 counts, and antiretroviral combinations. In addition, samples from INI-naïve patients were also sent to be used as controls. Most participating centers belonged to RIS (Red de Investigación en SIDA), the government-funded Spanish AIDS research network, which involves around 25 HIV clinics across the country and whose main characteristics were described elsewhere previously (17). All specimens that were examined in the current study were part of the repository collected for the SINRES study, a previous survey that characterized RAL failures virologically in a total of 106 patients (6). Signed informed consent was obtained from each individual.
Genotypic resistance analysis.
The analysis of the HIV integrase gene was performed by bulk sequencing using an in-house PCR protocol with primers and conditions previously described (7). Primary integrase resistance mutations were defined as those changes that caused a significant loss of drug susceptibility by themselves. This was the case for the Y143RHC, Q148HRK, and N155H mutations.
Phenotypic resistance analysis.
Viral RNA was isolated from all plasma samples by using NucliSENS EasyMAG (bioMérieux). One amplicon per sample containing the reverse transcriptase-integrase (RT-IN) regions was sequenced and cloned into an HXB2 backbone. Recombinant viruses were titrated and subjected to an antiviral experiment with MT4-LTR-eGFP cells, as previously described (20). Briefly, MT4-LTR-eGFP cells were inoculated with a titrated amount of virus in the presence of 3-fold dilutions of the compound tested. After 3 days of incubation at 37°C, infection was quantified by means of fluorescence microscopy measuring HIV Tat-induced enhanced green fluorescent protein (eGFP) expression. Using HIV-1 wild-type strain IIIB as a reference, fold change (FC) values were calculated by dividing the mean 50% effective concentration (EC50) for a recombinant virus stock by that for the reference strain. A biological cutoff (BCO) for RAL and EVG was calculated with a clonal database (991 clones from 153 clinical isolates) as the 97.5th percentile of the log FC phenotypes of patient-derived clonal viruses not containing any of the mutations listed in the RAL package insert label, including 74M, 92Q, 97A, 138A/K, 140A/S, 143C/H/R, 148H/K/R, 151I, 155H, 163R, 183P, 226C/D/F/H, 230R, and 232N, and/or not containing mutations with score of >0 for RAL-EVG by Stanford algorithm 6.0.11. Before the BCO was calculated, outliers (log FC > mean log FC plus 3 standard deviations) were removed (22). Thus, biological cutoffs were preliminarily established as an FC of 2 for RAL and an FC of 1.9 for EVG.
Statistical analysis.
Results are expressed as medians (interquartile ranges [IQRs]) and percentages. Comparisons were performed with nonparametric tests using Mann-Whitney or chi-square tests. FC values were log transformed for analyses of phenotypic resistance correlations using a bivariate analysis. All statistical analyses were carried out by using SPSS v15 software (SPSS Inc., Chicago, IL).
Nucleotide sequence accession numbers.
All sequences examined in this study have been submitted to the GenBank database under accession numbers JQ716857 to JQ716918.
Study population.
A total of 61 samples were examined: 21 belonging to INI-naïve patients and 40 obtained from patients experiencing early virological failure on RAL-containing regimens. All INI-naïve individuals were antiretroviral experienced. The main characteristics of this population are summarized in Table 1.
Table 1
Table 1
Main characteristics of the study population
Resistance testing for INI-naïve patients.
Phenotypic results for specimens collected from the 21 INI-naïve individuals showed that all but 1 (95.2%) were susceptible to RAL. The single sample displaying an FC of 2.4 for RAL did not harbor any primary or secondary known integrase resistance mutation. However, compared to reference sequences, the following changes in the integrase gene were present: E11D, S24G, D25E, S39C, M50IM, I72V, L101I, V201I, and S283G. In contrast, up to 8/21 (38%) INI-naïve samples displayed an FC above 1.9 for EVG. Neither primary nor secondary resistance changes were found in these specimens, as shown in Table 2.
Table 2
Table 2
Genotypic and phenotypic results for patients naïve to HIV integrase inhibitorsa
Resistance testing for RAL failures.
Overall, 11 out of 40 (27.5%) samples collected from patients experiencing early RAL failure harbored primary INI resistance mutations, including the Q148H/R (n = 5), N155H (n = 3), and Y143R (n = 2) mutations and a complex pattern including the Y143HY and N155H mutations (n = 1).
Fourteen (35%) samples displayed phenotypic FCs above 2 for RAL, including the 11 specimens with primary INI resistance mutations. Three samples, which did not contain any primary INI resistance change, displayed low FC values for RAL (2, 2.5, and 2.7, respectively). As a comparison, the median FC was 58.9 (IQR, 26.5 to 125.3) for the 11 patients with INI resistance mutations. The main characteristics of these patients are reported in Table 3, including information on RAL plasma levels as an indirect marker of drug adherence.
Table 3
Table 3
Genotypic and phenotypic results for patients failing on raltegravira
When EVG sensitivity testing was carried out, 19 (47.5%) RAL failures displayed impaired EVG sensitivity. Overall, the median FC was 7.71 (IQR, 2.48 to 99.93), but it was much higher in the 11 samples harboring primary INI resistance mutations than in the 8 samples without major integrase changes (FC of 99.93 [IQR, 46.92 to 99.93] versus 2.45 [IQR, 2.36 to 2.83]; P < 0.001). Table 3 reports the genotypic and phenotypic data for EVG in these patients.
Primary INI resistance mutations led to high-level resistance to both RAL and EVG although with slight differences. The Y143R mutation conferred a higher level of resistance to RAL than to EVG, with the FCs ranging from 26.5 to 58.9 and from 3.92 to 7.68, respectively. However, it is noteworthy that this change, which is not considered a primary resistance mutation for EVG, significantly compromised EVG susceptibility in the presence of secondary resistance mutations (T97A plus V151I for one specimen and L74M for another).
Impact of minor integrase changes on RAL and EVG susceptibilities.
Comparisons of RAL and EVG FCs in the presence or absence of changes at single integrase positions were performed by using nonparametric tests. Only samples without primary INI resistance mutations were considered for this purpose, and therefore, the analysis was carried out with a subset of 50 specimens. Changes at 5 positions were positively associated with increased FCs for RAL compared to the wild type. These changes were as follows: S24G/N, D25E, L74I, K215N, and Q221H/S. On the contrary, the K156N change reduced the FC for RAL compared to the wild type. Of note, the L74I and K215N mutations appeared together in the same specimen, the same way most of the S24G/N and D25E mutations appeared together. All this information is summarized in Table 4. With respect to EVG, the L45Q/V, V72I, and R263K mutations were associated with an increased FC, while the S119G/P/S/T, V126M/L, and Q216H mutations seemed to enhance EVG susceptibility in comparison with the wild type.
Table 4
Table 4
Phenotypic impact of minor changes in the HIV integrase gene in the absence of primary resistance mutations on susceptibility to raltegravir and elvitegravira
Cross-resistance between RAL and EVG.
Bivariate associations between FCs for RAL and EVG expressed as log values resulted in a significant positive correlation (R2 = 0.8; P < 0.001), supporting that there was a high degree of cross-resistance between both drugs. However, reduced susceptibility to EVG was more common than reduced susceptibility to RAL, as 27/61 (44.3%) samples displayed EVG resistance, in comparison with only 15/61 (24.6%) samples showing reduced susceptibility to RAL (P = 0.002).
Resistance to both RAL and EVG has been described to be associated mainly with changes at integrase positions 148 and 155. Our phenotypic results confirm the impact of these changes, since they conferred high FCs to both drugs. The Y143R mutation leads to the third RAL resistance pattern, and again, its impact on RAL susceptibility was confirmed in our study, showing high FC values. Interestingly, this mutation also impaired EVG susceptibility, showing an FC of 4 to 8 when the Y143R mutation was present along with other secondary changes. This is somewhat unexpected, since previous reports claimed that the Y143R mutation did not influence EVG susceptibility (5, 14, 18). Altogether, our results suggest that EVG activity is compromised in the presence of any of the RAL resistance patterns, including the Y143R mutation. Therefore, the sequential use of these drugs is not advisable upon failure with either of them.
A few samples in our study displayed small, but potentially clinically significant, reductions in susceptibility to integrase inhibitors, based upon the established biological cutoffs of FC values of 2.0 and 1.9 for RAL and EVG, respectively. The reduced sensitivity was more prominent for EVG in the absence of primary INI resistance mutations. One specimen from a subject failing on a RAL-containing regimen did not show any known INI resistance mutation but displayed FC values of 2.5 for RAL and 7.71 for EVG. This sample harbored only the R263K mutation as being potentially responsible for this effect on INI susceptibility. Interestingly, the R263K mutation was previously shown to be selected in vitro by EVG, conferring an FC of 5.2 to the drug (10). In the present study, this mutation also led to a slight but significant decrease in RAL susceptibility. Another patient displayed an FC of 2.7 for RAL despite lacking primary INI resistance mutations. However, the L74I mutation had been selected in this patient failing on a RAL-containing regimen. Given that the L74M mutation is a secondary resistance mutation generally selected along with the N155H mutation in patients failing on RAL-containing regimens (8, 15), we suggest that the L74I mutation might equally compromise RAL susceptibility.
Overall, the testing of samples collected from patients with RAL failures in the absence of primary INI resistance mutations allowed the recognition of certain minor changes that might impact INI susceptibility in a clinically relevant manner. This was the case for the S24G/N, D25E, L74I, K215N, and Q221H/S changes for RAL and the L45Q/V, V72I, and R263K changes for EVG. Additional resistance studies are being performed by Virco to clear up the phenotypic effect of each of these changes. However, their clinical impact should be further investigated with larger groups of patients experiencing INI failures.
Most patients displaying resistance to RAL in our study also exhibited a reduced EVG susceptibility. The extent of cross-resistance was high for all different resistance patterns and may have important clinical implications regarding the consideration of the sequential use of RAL and EVG. Moreover, it was intriguing that EVG showed increased FC values more often than RAL, suggesting that integrase changes had a greater influence on EVG. Hypothetically, our findings could be explained by the faster time of dissociation from the viral integrase for EVG than for RAL, with half-lives of 2.4 and 9 h, respectively (9).
The variability at the viral integrase has been shown to be greater in antiretroviral-experienced than in drug-naïve patients (1, 7, 21). All our patients, regardless of RAL exposure, were antiretroviral experienced, which might have led to a higher rate of polymorphisms, providing an explanation of the relatively high proportion of subjects with slight reductions in RAL and especially EVG susceptibilities in INI-naïve patients.
In summary, our results for the testing of phenotypic and genotypic samples from patients with RAL failures and controls support that susceptibility to RAL and EVG is impaired mainly by the Q148H/R, N155H, and/or Y143R resistance mutation. Slight reductions in susceptibility to any of these drugs can occur in the presence of other integrase changes. The wide extent of cross-resistance between RAL and EVG should preclude their sequential use.
ACKNOWLEDGMENTS
Members of the Spanish Integrase Resistance (SINRES) Group are as follows: J. Pedreira (Hospital Juan Canalejo, La Coruña, Spain); J. A. Iribarren (Hospital de Donostia, San Sebastián, Spain); J. Solá (Hospital de Navarra, Pamplona, Spain); M. J. Téllez and V. Estrada (Hospital Clínico San Carlos, Madrid, Spain); S. García and J. R. Arribas (Hospital La Paz, Madrid, Spain); L. Santos (Hospital de la Princesa, Madrid, Spain); P. Miralles (Hospital Gregorio Marañón, Madrid, Spain); J. E. Losa (Hospital Universitario Fundación de Alcorcón, Madrid, Spain); M. Cervero (Hospital Severo Ochoa, Madrid, Spain); J. Sanz (Príncipe de Asturias, Madrid, Spain); C. Barros (Hospital de Móstoles, Madrid, Spain); M. de Górgolas (Fundación Jiménez Díaz, Madrid, Spain); E. Ribera and E. Caballero (Hospital Vall d'Hebrón, Barcelona, Spain); C. Vidal and M. Riera (Hospital Son Dureta, Palma de Mallorca, Spain); C. Gómez (Complejo Hospitalario de Toledo); A. Chocarro (Virgen de la Concha, Zamora, Spain); M. J. Galindo (Hospital Clínico Universitario, Valencia, Spain); F. Gutiérrez (Hospital General Universitario, Elche, Spain); I. Viciana and J. Santos (Hospital Virgen de la Victoria, Málaga, Spain); M. Omar (Hospital Ciudad de Jaén); A. Collado and C Gálvez (Hospital Torrecardenas, Almeria, Spain); A. B. Lozano and J. M. Fernández (Hospital Poniente, Almería, Spain); V. Gutiérrez-Ravé (Hospital de Motril, Granada, Spain); F. García, M. A. López Ruz, C. Hidalgo, and J. Pasquau (Hospital Universitario Virgen de las Nieves, Granada, Spain); F. García, V. Guillot, and J. Hernández-Quero (Hospital Universitario San Cecilio Granada); J. A. Pineda (Hospital de Valme, Seville, Spain); and C. Garrido, L. Anta, C. de Mendoza, and V. Soriano (Hospital Carlos III, Madrid, Spain).
Footnotes
Published ahead of print 26 March 2012
1. Ceccherini-Silberstein F, et al. 2010. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J. Antimicrob. Chemother. 65:2305–2318. [PubMed]
2. Cooper DA, et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355–365. [PubMed]
3. DeGruttola V, et al. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5:41–48. [PubMed]
4. DeJesus E, et al. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1–5. [PubMed]
5. Delelis O, et al. 2010. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob. Agents Chemother. 54:491–501. [PMC free article] [PubMed]
6. Garrido C, et al. 2012. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. AIDS Res. Hum. Retroviruses 28:156–164. [PubMed]
7. Garrido C, et al. 2010. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J. Antimicrob. Chemother. 65:320–326. [PubMed]
8. Hazuda D, et al. 2007. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection. Antivir. Ther. 12(Suppl 1):10.
9. Hightower KE, et al. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55:4552–4559. [PMC free article] [PubMed]
10. Jones G, et al. 2007. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor GS-9137 (JTK-303), abstr 627. Abstr. 14th Conf. Retrovirus Opportun. Infect., Los Angeles, CA, 25 to 28 February 2007.
11. Lennox JL, et al. 2010. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immune Defic. Syndr. 55:39–48. [PubMed]
12. Martinez-Cajas J, Wainberg M. 2007. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 76:203–221. [PubMed]
13. McColl D, et al. 2007. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antivir. Ther. 12(Suppl 1):S11.
14. Métifiot M, et al. 2011. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 25:1175–1178. [PubMed]
15. Miller M, et al. 2008. Longitudinal analysis of resistance to the HIV-1 integrase inhibitor RAL: results from P005 a phase II study in treatment experienced patients. Antivir. Ther. 13(Suppl 3):A8.
16. Miller V, Larder B. 2001. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir. Ther. 6(Suppl 3):25–44. [PubMed]
17. Pérez Cachafeiro S, et al. 2009. Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997–2006. Clin. Infect. Dis. 48:1467–1470. [PubMed]
18. Reigadas S, et al. 2010. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to raltegravir and impact the enzyme functions. PLoS One 5:e10311. [PMC free article] [PubMed]
19. Steigbigel RT, et al. 2010. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin. Infect. Dis. 50:605–612. [PubMed]
20. Van Baelen K, et al. 2009. A combined genotypic and phenotypic HIV type 1 recombinant virus assay for the reverse transcriptase and integrase genes. J. Virol. Methods 161:231–239. [PubMed]
21. Van Hal S, et al. 2009. HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology 6:12. [PMC free article] [PubMed]
22. Verlinden Y, et al. 2005. Assessment of the Antivirogram performance over time, including a revised definition of biological test cut-off values. Antivir. Ther. 10(Suppl):S51.
Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of
American Society for Microbiology (ASM)